DGIdb - RAMUCIRUMAB Drug Record

RAMUCIRUMAB chembl:CHEMBL1743062 ApprovedAntineoplastic

Alternate Names:

1121B
CYRAMZA
IMC-1121B
LY3009806
RAMUCIRUMAB
chemidplus:947687-13-0
drugbank:05578
chembl:CHEMBL1743062
rxcui:1535922

Drug Info:

FDA Approval	Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer
Drug Class	Therapeutic Antibodies
FDA Approval	not approved
Drug Class	antibody
Drug Indications	antineoplastic agent

(6 More Sources)

Publications:

Goodkin et al., 1990, Arteriovenous malformation and glioma: coexistent or sequential? Case report., J. Neurosurg.
Spratlin et al., 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2., J. Clin. Oncol.
Tabernero et al., 2015, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study., Lancet Oncol.
Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.

RAMUCIRUMAB KDR

Interaction Score: 0.7

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name IMC-1121B

Novel drug target Established target

Notes

PMIDs:
2182794 20048182

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions GuideToPharmacology TTD
RAMUCIRUMAB PDGFRA

Interaction Score: 0.32

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome
RAMUCIRUMAB KRAS

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ramucirumab + FOLFIRI

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
25877855

Sources:
JAX-CKB PharmGKB
RAMUCIRUMAB ALK

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RAMUCIRUMAB ERBB2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase III

Response Type no benefit

PMIDs:
25185099

Sources:
JAX-CKB
RAMUCIRUMAB EGFR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA

MyCancerGenome: RAMUCIRUMAB
- Version: 20-Jun-2017
Alternate Names:

CYRAMZA Trade Name

IMC-1121B Development Name

IMC-3G3 Development Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer

Publications:
TdgClinicalTrial: IMC-1121B
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class antibody

FDA Approval not approved

Publications:

JAX-CKB: Ramucirumab

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Tabernero et al., 2015, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study., Lancet Oncol.

Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.

Spratlin et al., 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2., J. Clin. Oncol.

TALC: RAMUCIRUMAB
- Version: 12-May-2016
Alternate Names:

IMC-1121B Drug Synonym

IMC-3G3 Drug Synonym

RAMUCIRUMAB Drug Generic Name

Drug Info:

Publications:
TTD: Ramucirumab
- Version: 2020.06.01
Alternate Names:

D09HVD TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103962
- Version: 29-September-2020
Alternate Names:

RAMUCIRUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1743062
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1743062
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
PharmGKB: ramucirumab
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
FDA: Ramucirumab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

combination therapy	Ramucirumab + FOLFIRI
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Phase III
Response Type	no benefit

CYRAMZA	Trade Name
IMC-1121B	Development Name
IMC-3G3	Development Name

IMC-1121B	Drug Synonym
IMC-3G3	Drug Synonym
RAMUCIRUMAB	Drug Generic Name

antibody (inhibitory)
antagonist (inhibitory)
inhibitor (inhibitory)

Trial Name	IMC-1121B
Novel drug target	Established target
Notes

RAMUCIRUMAB Drug Record

RAMUCIRUMAB chembl:CHEMBL1743062 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

RAMUCIRUMAB KDR

Interaction Types & Directionality: antibody (inhibitory) antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name IMC-1121B Novel drug target Established target Notes

PMIDs: 2182794 20048182

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions GuideToPharmacology TTD

RAMUCIRUMAB PDGFRA

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC MyCancerGenome

RAMUCIRUMAB KRAS

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ramucirumab + FOLFIRI Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 25877855

Sources: JAX-CKB PharmGKB

RAMUCIRUMAB ALK

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

RAMUCIRUMAB ERBB2

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Phase III Response Type no benefit

PMIDs: 25185099

Sources: JAX-CKB

RAMUCIRUMAB EGFR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

MyCancerGenome: RAMUCIRUMAB

Alternate Names: CYRAMZA Trade Name IMC-1121B Development Name IMC-3G3 Development Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer

Publications:

TdgClinicalTrial: IMC-1121B

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class antibody FDA Approval not approved

Publications:

JAX-CKB: Ramucirumab

Alternate Names:

Drug Info:

TALC: RAMUCIRUMAB

Alternate Names: IMC-1121B Drug Synonym IMC-3G3 Drug Synonym RAMUCIRUMAB Drug Generic Name

Drug Info:

Publications:

TTD: Ramucirumab

Alternate Names: D09HVD TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178103962

Alternate Names: RAMUCIRUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1743062

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1743062

Alternate Names:

Drug Info:

Publications:

PharmGKB: ramucirumab

Alternate Names:

Drug Info:

Publications:

FDA: Ramucirumab

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name IMC-1121B

Novel drug target Established target

Notes

PMIDs:
2182794 20048182

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ramucirumab + FOLFIRI

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
25877855

Sources:
JAX-CKB PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase III

Response Type no benefit

PMIDs:
25185099

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Alternate Names:

CYRAMZA Trade Name

IMC-1121B Development Name

IMC-3G3 Development Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer

Drug Info:

Drug Indications antineoplastic agent

Drug Class antibody

FDA Approval not approved

Alternate Names:

IMC-1121B Drug Synonym

IMC-3G3 Drug Synonym

RAMUCIRUMAB Drug Generic Name

Alternate Names:

D09HVD TTD Drug ID

Alternate Names:

RAMUCIRUMAB GuideToPharmacology Ligand Name